Plus Therapeutics Inc (NASDAQ: PSTV) has experienced a decline in its stock price by -14.49 compared to its previous closing price of 1.38. However, the company has seen a gain of 73.84% in its stock price over the last five trading days. zacks.com reported 2025-03-21 that The FDA conditionally accepts Plus Therapeutics’ new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.
Is It Worth Investing in Plus Therapeutics Inc (NASDAQ: PSTV) Right Now?
The 36-month beta value for PSTV is at 0.43. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PSTV is 11.48M, and currently, shorts hold a 1.22% of that float. The average trading volume for PSTV on March 24, 2025 was 14.87M shares.
PSTV’s Market Performance
PSTV stock saw a decrease of 73.84% in the past week, with a monthly decline of -1.66% and a quarterly a decrease of 10.28%. The volatility ratio for the week is 74.04%, and the volatility levels for the last 30 days are 56.49% for Plus Therapeutics Inc (PSTV).. The simple moving average for the past 20 days is 29.27% for PSTV’s stock, with a -15.18% simple moving average for the past 200 days.
Analysts’ Opinion of PSTV
Many brokerage firms have already submitted their reports for PSTV stocks, with D. Boral Capital repeating the rating for PSTV by listing it as a “Buy.” The predicted price for PSTV in the upcoming period, according to D. Boral Capital is $9 based on the research report published on March 17, 2025 of the current year 2025.
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see PSTV reach a price target of $8. The rating they have provided for PSTV stocks is “Buy” according to the report published on January 25th, 2021.
Maxim Group gave a rating of “Buy” to PSTV, setting the target price at $6 in the report published on October 16th of the previous year.
PSTV Trading at 8.21% from the 50-Day Moving Average
After a stumble in the market that brought PSTV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.81% of loss for the given period.
Volatility was left at 56.49%, however, over the last 30 days, the volatility rate increased by 74.04%, as shares sank -1.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.84% lower at present.
During the last 5 trading sessions, PSTV rose by +73.84%, which changed the moving average for the period of 200-days by -47.56% in comparison to the 20-day moving average, which settled at $0.9128. In addition, Plus Therapeutics Inc saw 2.61% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PSTV starting from Hawkins Richard J, who purchase 4,000 shares at the price of $1.50 back on Sep 13 ’24. After this action, Hawkins Richard J now owns 15,188 shares of Plus Therapeutics Inc, valued at $5,996 using the latest closing price.
Hawkins Richard J, the Director of Plus Therapeutics Inc, purchase 6,285 shares at $1.35 during a trade that took place back on Sep 12 ’24, which means that Hawkins Richard J is holding 11,188 shares at $8,512 based on the most recent closing price.
Stock Fundamentals for PSTV
Current profitability levels for the company are sitting at:
- -3.43 for the present operating margin
- 0.26 for the gross margin
The net margin for Plus Therapeutics Inc stands at -3.02. The total capital return value is set at 2.85. Equity return is now at value -522.50, with -127.22 for asset returns.
Based on Plus Therapeutics Inc (PSTV), the company’s capital structure generated -1.92 points at debt to capital in total, while cash flow to debt ratio is standing at -3.3. The debt to equity ratio resting at -0.66. The interest coverage ratio of the stock is -3.93.
Currently, EBITDA for the company is -12.69 million with net debt to EBITDA at -0.18. When we switch over and look at the enterprise to sales, we see a ratio of 3.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.44.
Conclusion
In conclusion, Plus Therapeutics Inc (PSTV) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
